Back
Alnylam Pharmaceuticals, Inc. (ALNY)
BiotechnologyALNY · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$232.67
+3.63%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$2.33
ROE
90.4%
Gross margin
80.8%
Debt/Equity
2.76x
Revenue growth
96.4%
Alnylam Pharmaceuticals, Inc. — company intelligence
Earnings surprises
Q2 2026$1.21 vs $1.59 est-23.7%
Q1 2026$1.51 vs $0.98 est+53.8%
Q4 2025$0.82 vs $1.15 est-28.5%
Q3 2025$2.11 vs $0.76 est+177.2%
Analyst consensus · 38 analysts
29 Buy9 Hold0 Sell
Updated Oct 8, 2026
Insider activity · 90 days
1 buy1 sellnet -1,651 shares
SUPRAN BRYANSell 1,758 · Oct 2, 2026
Greenstreet YvonneBuy 107 · Sep 19, 2026
Recent SEC filings
4 — Insider transaction reportOct 6, 2026
4 — Insider transaction reportSep 22, 2026
8-K — Material event reportJul 30, 2026
Latest news
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside — SeekingAlpha · 2w ago
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.